5.47
-2.32%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sino Biopharmaceutical
Its shares trade on HKEX under the ticker 1177.HK. It has been listed since 8 December 2003. In the fiscal year to 31 December 2025, it reported revenue of CN¥37.12bn and net income of CN¥2.73bn. At that date it held total assets of CN¥88.67bn and shareholders' equity of CN¥35.78bn.
Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. The company employs 23,302 full-time employees The company went IPO on 2003-12-08. The firm operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The firm is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Dec 2003
- Employees
- 23,302
- Website
- sinobiopharm.com ↗
Leadership
Pay as last reported
- Ms. Y Y TseExecutive Chairwoman of the Board, since 2015CN¥49.7m
- Mr. S. Y. TseChief Executive Officer, Executive Director, since 2019CN¥49.7m
- Ms. Cheung Ling ChengExecutive Vice Chairwoman of the Board, since 2005CN¥43.1m
- Mr. Ping TseSenior Executive Vice Chairman of the Board, since 2020CN¥49.5m
- Ms. Chunling LiChief Financial Officer, since 2022
- Mr. Benjamin ToogoodChief Executive Officer of invoX Pharma Limited and Head of Globalisation of Sino Biopharm
- Mr. Hsin TseSenior Vice President, Executive Director, since 2021CN¥6.4m
- Mr. Song JinVice President - Public Affairs, Medicines Policies and ESG
- Mr. Zhoushan TianGeneral Manager of NJCTT, Executive DirectorCN¥1.9m
- Mr. Sean ChenChief Strategic Officer
- Mr. Oi Nin ChanCompany Secretary
- Mr. Dakui LiIndependent Non-Executive DirectorCN¥376,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 91
- Environment
- 99
- Social
- 99
- Governance
- 76
- Direct emissions (scope 1)
- 17,046.22 t
- Energy emissions (scope 2)
- 222,193.4 t
- Women in the workforce
- 47.56%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sino Biopharmaceutical Ltd is a reputable and established company in the biopharmaceutical industry.
- The company has a strong portfolio of innovative and high-quality pharmaceutical products.
- Sino Biopharmaceutical Ltd has a robust distribution network, enabling wide market reach.
Weaknesses
- The company heavily relies on the Chinese market, which may pose risks due to regulatory changes or economic fluctuations.
- Sino Biopharmaceutical Ltd faces intense competition from other domestic and international pharmaceutical companies.
- The company's research and development capabilities may require further investment to stay competitive in the industry.
Opportunities
- The growing demand for healthcare services presents an opportunity for Sino Biopharmaceutical Ltd to expand its market share.
- Increasing government support and investments in the biopharmaceutical sector create favorable conditions for business growth.
- The company can explore strategic partnerships or acquisitions to access new markets or expand its product offerings.
Threats
- Uncertain global economic conditions, such as trade wars or recessions, may impact Sino Biopharmaceutical Ltd's international operations.
- Stringent regulatory requirements and compliance standards can pose challenges for the company's product development and commercialization efforts.
- Emerging competitors and technological advancements in the industry may disrupt Sino Biopharmaceutical Ltd's market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.